Intellia Therapeutics Inc Stock
Intellia Therapeutics Inc gained 0.830% compared to yesterday.
Our community is currently high on Intellia Therapeutics Inc with 23 Buy predictions and 6 Sell predictions.
Based on the current price of 9.0 € the target price of 26 € shows a potential of 188.89% for Intellia Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Intellia Therapeutics Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 0.830% | 13.245% | 9.575% | -10.219% | 14.348% | -74.406% | -85.118% |
| Chromadex Corp | - | 3.774% | 0.000% | 7.843% | 0.000% | 204.540% | 39.594% |
| Starpharma Holdings Ltd. | 4.620% | 5.699% | 5.699% | 242.857% | 4.082% | -50.701% | -78.182% |
| Polynovo Ltd | -1.450% | -0.730% | 0.000% | -43.802% | 0.000% | -55.556% | -67.619% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
Show more
Ratings data for NTLA provided by MarketBeat
News
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
The "Magnificent Seven" stocks, a group of (mostly) tech giants, are among the most covered companies on Wall Street. The general sentiment about these corporations is that they boast attractive
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Intellia Therapeutics (NASDAQ: NTLA), a small-cap biotech company, has some notable bulls. One of them is Cathie Wood, the CEO of Ark Invest. The innovation-focused investment firm has long held